NEW YORK, April 29, 2022 Pfizer Inc. (NYSE: PFE) today shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for post-exposure prophylactic use.

In this trial, compared to placebo, Pfizer observed risk reductions of 32% and 37% in adults who received PAXLOVID for five and ten days, respectively, to prevent infection.
These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met.

According to this, the trial data used to obtain EUA designation showed:

  • 89% relative risk reduction of progression to severe COVID for a high risk group.
  • For those with COVID immunity absolute risk reduction was only 1%.
  • The trial was done at a time when Delta was predominant and when fewer people had naturally acquired or vaccine-induced immunity to COVID-19, raising questions about whether the $530 five-day treatment is even effective against the newer variants predominant today.
  • It is unknown how it will perform with other variants.
Pfizer foresees $54 billion in global sales this year — $32 billion from its COVID-19 vaccine and $22 billion from Paxlovid.

Please see Full Emergency Use Authorization (EUA) Prescribing Information available at and